TICKERNERD
Menu
RARERAREHealthcare · Biotechnology

RARE Stock Forecast: Ultragenyx Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$26
+0.42% on the day

The 19 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. hold a median 12-month price target of $46 — +73.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 13 Aug 2026 — in the upper half.

Market cap
$2.6B
Ticker Nerd rank
50 / 100
Median analyst target
$46
Analysts covering
19
Total return, dividends reinvested
1W
+2.2%
1M
−17.3%
YTD
+15.2%
1Y
−8.7%
From 52W high
−27.5%
From 52W low
+43.2%
$19
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RARE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ultragenyx Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
83
Revisions
73
Accruals
61
Volatility
60
Quality
57
Growth
42
Momentum
38
Size
33
Issuance
12

Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RARE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RARE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26RAREHigh $96Median $46Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says19 analysts
17 Buy2 Hold0 Sell
Low $27Median $46High $96

The green dot is the last close — the median target sits +73.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 13 moved it down.

DateFirmActionRatingTarget
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
5 Aug 2026Wells FargoMaintainsOverweight$47 → $45
4 Aug 2026GuggenheimMaintainsBuy$43 → $35
7 July 2026RBC CapitalMaintainsOutperform$35 → $40
21 May 2026Cantor FitzgeraldMaintainsOverweight$84 → $96
8 May 2026GuggenheimMaintainsBuy$52 → $43
8 May 2026WedbushMaintainsNeutral$27 → $26
6 May 2026WedbushMaintainsNeutral$27 → $26
6 May 2026Wells FargoMaintainsOverweight$45 → $47
29 Apr 2026BarclaysMaintainsOverweight$44 → $43
16 Apr 2026Morgan StanleyMaintainsOverweight$50 → $67
24 Mar 2026Goldman SachsDowngradeNeutral$61 → $25
12 Mar 2026JP MorganMaintainsOverweight$120 → $74
18 Feb 2026Canaccord GenuityMaintainsBuy$128 → $79
18 Feb 2026Evercore ISI GroupMaintainsOutperform$37 → $34
17 Feb 2026Evercore ISI GroupMaintainsOutperform$39 → $37
17 Feb 2026HC Wainwright & Co.MaintainsBuy$60 → $50
17 Feb 2026WedbushReiteratesNeutral$25
3 Feb 2026HC Wainwright & Co.ReiteratesBuy$60
5 Jan 2026GuggenheimMaintainsBuy$64 → $52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RARE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RARE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Ultragenyx Pharmaceutical, Inc. (RARE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.5×

Cheaper than 89% of US stocks

Price / sales
3.6×

Cheaper than 36% of US stocks

Price / book
−9.4×

Cheaper than 97% of US stocks

EV / EBITDA
−7.5×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
28.1%

Higher than 77% of US stocks

Earnings growth (YoY)
28.5%

Higher than 65% of US stocks

Gross margin
84.1%

Higher than 93% of US stocks

Operating margin
−35.0%

Higher than 19% of US stocks

Net margin
−81.7%

Higher than 7% of US stocks

Returns & dividend
Return on equity
787.7%

Higher than 99% of US stocks

Return on assets
−24.2%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RARE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RAREUltragenyx Pharmaceutical, Inc.$2.6B
50
TRVITrevi Therapeutics, Inc.$2.6B
53
ATAIAtai Beckley, Inc.$2.6B
26
NKTRNektar Therapeutics$2.5B
53
COAGHemab Therapeutics Holdings, Inc.$2.5B
2
BEAMBeam Therapeutics, Inc.$2.7B
49
SLSSELLAS Life Sciences Group, Inc.$2.5B
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ultragenyx Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RARE news & analysis

Ultragenyx: Undervalued Ahead Of Two FDA Decisions

Seeking Alpha · 14 Aug 2026positive

A Seeking Alpha article discusses Ultragenyx ahead of two near-term FDA decisions: one for DTX401 on Aug 23 and another for UX111 on Sept 19. The piece argues the stock is undervalued, with DTX401 seen as having a cleaner regulatory case and UX111 a credible approval path.

Why it matters — RARE watchers would care because the outcome of these two FDA decisions could materially shape the company's near-term outlook.

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Zacks Investment Research · 5 Aug 2026positive

Ultragenyx beat Q2 earnings estimates, with revenues jumping year over year to a record quarterly high. The growth was driven by higher product sales across its portfolio.

Why it matters — A RARE watcher would care because the earnings beat and record quarterly revenue signal strong commercial momentum across Ultragenyx's product portfolio.

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Ultragenyx Pharmaceutical Inc.'s (RARE) Q2 2026 earnings call. The excerpt provides the headline and source only, with no details on the company's results or statements.

Why it matters — A RARE watcher would care because the transcript is the official record of management's quarterly earnings commentary, but this excerpt contains no substantive information to assess the company's performance.

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026neutral

Ultragenyx reported second-quarter 2026 revenue of $214 million, driven by growth across its commercial rare-disease portfolio. The company is also preparing for potential regulatory decisions on two gene therapies and a late-stage data readout in Angelman syndrome.

Why it matters — The quarterly revenue figures and upcoming regulatory and clinical catalysts are key indicators of near-term performance and pipeline progress for RARE watchers.

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 5 Aug 2026neutral

Ultragenyx (RARE) reported earnings for the quarter ended June 2026, with the coverage noting attention on how the company's top- and bottom-line results and key metrics compare to Wall Street estimates and year-ago figures.

Why it matters — RARE watchers would care because this update highlights how the company's latest quarterly performance stacks up against analyst expectations and prior-year results.

FAQ

Frequently asked questions about RARE stock

What is the RARE stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. have a median 12-month price target of $46, with estimates ranging from $27 to $96. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RARE stock a buy right now?

Of the 19 analysts covering Ultragenyx Pharmaceutical, Inc., 17 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ultragenyx Pharmaceutical, Inc. 50 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RARE?

As at 13 Aug 2026, Ultragenyx Pharmaceutical, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).

Will RARE stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +73.7% from the last close, and Ticker Nerd's factor model ranks Ultragenyx Pharmaceutical, Inc. 50 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RARE stock forecast for 2030?

No analyst covering Ultragenyx Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $96 over the next 12 months.

How has RARE stock performed over the past year?

Ultragenyx Pharmaceutical, Inc. returned -8.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ultragenyx Pharmaceutical, Inc. do?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases.

What is the latest news on RARE?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Ultragenyx: Undervalued Ahead Of Two FDA Decisions". A Seeking Alpha article discusses Ultragenyx ahead of two near-term FDA decisions: one for DTX401 on Aug 23 and another for UX111 on Sept 19. The piece argues the stock is undervalued, with DTX401 seen as having a cleaner regulatory case and UX111 a credible approval path.

Company

About Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Ultragenyx Pharmaceutical Inc. currently markets medicines for conditions such as X-linked hypophosphatemia, mucopolysaccharidosis VII, and certain metabolic disorders, while also maintaining a pipeline across bone, endocrine, metabolic, muscle, and central nervous system disease areas. The company works to address serious, often debilitating disorders with limited treatment options through multiple drug modalities, including biologics and small molecules. Its business centers on identifying unmet medical needs in rare disease and delivering specialized treatments to patients, healthcare providers, and medical institutions. Headquartered in Novato, California, and founded in 2010, Ultragenyx Pharmaceutical Inc. plays a notable role in the rare-disease biopharmaceutical market.

CEO Dr. Emil D. Kakkis M.D., Ph.D. · 1,294 employees · United States · https://www.ultragenyx.com